


Stanford



Lauren Maeda

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

CLINICAL OFFICES

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm CC2325

MC 6505

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 498-5030

Bio

CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Lymphoma
- Medical Oncology

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Clinical Assistant Professor, Medicine - Hematology

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2011) CA
- Medical Education: Stanford University School of Medicine Registrar (2006) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2012)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2009)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Recruiting
- Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma, Recruiting
- Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma, Recruiting

- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, Not Recruiting
- A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas, Not Recruiting
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Not Recruiting
- A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies, Not Recruiting
- A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects # 65 Years With Newly-Diagnosed Acute Myeloid Leukemia, Not Recruiting
- A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors, Not Recruiting
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO), Not Recruiting
- A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia., Not Recruiting
- A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma, Not Recruiting
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma, Not Recruiting
- A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma, Not Recruiting
- A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma, Not Recruiting
- A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome, Not Recruiting
- A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6, Not Recruiting
- A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies, Not Recruiting
- A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Not Recruiting
- Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma, Not Recruiting
- Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma, Not Recruiting
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting
- Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma, Not Recruiting
- Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma, Not Recruiting
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies, Not Recruiting
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting
- Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission, Not Recruiting

- Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia, Not Recruiting
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT), Not Recruiting
- Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer, Not Recruiting
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma, Not Recruiting
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia, Not Recruiting
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia, Not Recruiting
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma, Not Recruiting
- Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087), Not Recruiting
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting

Publications

PUBLICATIONS

- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; JCO2018785246
- **Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA** *SCIENCE TRANSLATIONAL MEDICINE*
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., Zhou, L., Glover, C., Visser, et al
2016; 8 (364)
- **Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma** *NEW ENGLAND JOURNAL OF MEDICINE*
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., Staudt, L. M., Jaffe, E. S., Wilson, et al
2013; 368 (15): 1408-1416
- **A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma** *LEUKEMIA & LYMPHOMA*
Warsch, S., Hosein, P. J., Maeda, L. S., Alizadeh, A. A., Lossos, I. S.
2012; 53 (7): 1299-1305
- **Clinical Outcome Prediction by MicroRNAs in Human Cancer: A Systematic Review** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Nair, V. S., Maeda, L. S., Ioannidis, J. P.
2012; 104 (7): 528-540
- **STAGE I-IIIa NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS USEFUL? THE STANFORD EXPERIENCE** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
Advani, R. H., Hoppe, R. T., Maeda, L. S., Baer, D. M., Mason, J., Rosenberg, S. A., Horning, S. J.
2011; 81 (5): 1374-1379
- **Current concepts and controversies in the management of early stage Hodgkin lymphoma** *LEUKEMIA & LYMPHOMA*
Maeda, L. S., Lee, M., Advani, R. H.

2011; 52 (6): 962-971

- **The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma** *CURRENT OPINION IN ONCOLOGY*
Maeda, L. S., Advani, R. H.
2009; 21 (5): 397-400
- **Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease** *9th International Conference on Malignant Lymphoma*
Advani, R., Maeda, L., Lavori, P., Quon, A., Hoppe, R., Breslin, S., Rosenberg, S. A., Horning, S. J.
AMER SOC CLINICAL ONCOLOGY.2007: 3902-7
- **Transcription arrest at an abasic site in the transcribed strand of template DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*
Tornaletti, S., Maeda, L. S., Hanawalt, P. C.
2006; 19 (9): 1215-1220
- **Transcriptional inhibition by an oxidized abasic site in DNA** *CHEMICAL RESEARCH IN TOXICOLOGY*
Wang, Y. L., Sheppard, T. L., Tornaletti, S., Maeda, L. S., Hanawalt, P. C.
2006; 19 (2): 234-241
- **Effect of 8-oxoguanine on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *DNA REPAIR*
Silvia, T. A., Maeda, L. S., Kolodner, R. D., Hanawalt, P. C.
2004; 3 (5): 483-494
- **Effect of thymine glycol on transcription elongation by T7 RNA polymerase and mammalian RNA polymerase II** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Tornaletti, S., Maeda, L. S., Lloyd, D. R., Reines, D., Hanawalt, P. C.
2001; 276 (48): 45367-45371